Results 71 to 80 of about 414,372 (151)
Use of short-acting insulin aspart in managing older people with diabetes
, 2009 Eltayeb Marouf, Alan J SinclairInstitute of Diabetes for Older People – IDOP, Bedfordshire and Hertfordshire Postgraduate Medical School, University of Bedfordshire, UKAbstract: Type 2 diabetes mellitus affects 5.9% of the world adult population ...
Eltayeb Marouf, Alan J Sinclair
core
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
, 2009 Paul ValensiDepartment of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, Bondy, FranceAbstract: The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have ...
Paul Valensi
core
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Faisal Hashim +2 more
doaj +1 more source
Faster aspart insulin (fiasp®)
, 2018 peer reviewedFast-acting insulin aspart (faster aspart), commercialized under the trade name of Fiasp(R), is insulin aspart in a new formulation aiming to mimic the physiologic prandial insulin release more closely than currently available rapid-acting ...
Scheen, André, Paquot, Nicolas
core
Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes : systematic review and economic evaluation [PDF]
, 2010 Based on the totality of evidence, using observational studies to supplement the limited data from randomised trials against best MDI, CSII provides some advantages over MDI in T1DM for both children and adults.
P Royle +13 more
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Debmalya Sanyal +2 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66 726) in routine clinical care ...
Othmane Laaribi
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Sunil M Jain +4 more
doaj +1 more source
Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A1chieve Study [PDF]
, 2014 \ua9 2014, The Author(s).Conclusion: Insulin aspart therapy was well tolerated and was associated with improved glucose control over 24 weeks in people with T2DM.Methods: Insulin-na\uefve and insulin-experienced people with T2DM in routine clinical care ...
Hajjaji I +5 more
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Sanjay Kalra +3 more
doaj +1 more source